Clinical Trial Update: Conversion Pharmacodynamic Study in Stable Renal Transplant Patients Receiving Tacrolimus Two Times a Day to a New Formulation of Tacrolimus - LCP Tacro - 1 Time a Day. [Phase 4]

View source ↗

Summary

Phase 4 trial updating pharmacodynamic conversion from twice-daily tacrolimus to once-daily LCP Tacro in stable renal transplant patients; completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplant

Drugs mentioned

• LCP-Tacro (tacrolimus)
• Tacrolimus (Tacrolimus)

Snippet

Sponsor: Hospital Universitari de Bellvitge | Conditions: Kidney Transplant; Complications | Phase 4 | Status: COMPLETED